$7.96
5.49% today
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US81728A1088
Symbol
SNSE

Sensei Biotherapeutics Inc Stock price

$7.96
+0.75 10.40% 1M
-1.30 14.00% 6M
-1.84 18.79% YTD
-4.03 33.61% 1Y
-30.44 79.27% 3Y
-372.04 97.91% 5Y
-372.04 97.91% 10Y
-372.04 97.91% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.41 5.49%
ISIN
US81728A1088
Symbol
SNSE
Industry

Key metrics

Basic
Market capitalization
$9.5m
Enterprise Value
$-18.8m
Net debt
positive
Cash
$28.6m
Shares outstanding
1.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.8
P/B
0.4
Financial Health
Equity Ratio
84.6%
Return on Equity
-78.6%
ROCE
-102.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-27.8m | $-31.9m
EBIT
$-28.6m | $-30.6m
Net Income
$-26.8m | $-27.3m
Free Cash Flow
$-24.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
10.4% | -5.1%
EBIT
11.8% | 3.2%
Net Income
9.6% | 9.4%
Free Cash Flow
0.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-21.3
FCF per Share
$-19.3
Short interest
0.9%
Employees
15
Rev per Employee
$0.0
Show more

Is Sensei Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Sensei Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Sensei Biotherapeutics Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Sensei Biotherapeutics Inc forecast:

Buy
89%
Hold
11%

Financial data from Sensei Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
16% 16%
-
- Research and Development Expense 15 15
14% 14%
-
-28 -28
10% 10%
-
- Depreciation and Amortization 0.73 0.73
45% 45%
-
EBIT (Operating Income) EBIT -29 -29
12% 12%
-
Net Profit -27 -27
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about Sensei Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sensei Biotherapeutics Inc Stock News

Neutral
The Motley Fool
17 days ago
Sensei (SNSE) Q2 Loss Narrows 31%
Neutral
GlobeNewsWire
17 days ago
- Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quart...
Negative
Finbold
18 days ago
While the broader stock market suffered steep losses on Friday amid trade policy shifts and troubling economic data, select health technology equities stood out.
More Sensei Biotherapeutics Inc News

Company Profile

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation of immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Head office United States
CEO John Celebi
Employees 15
Founded 1999
Website www.senseibio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today